Bruker(BRKR) ZACKS·2024-11-11 16:31Company Overview - Bruker Corporation (BRKR) announced a new technology, EpicIF, to enhance its CellScape Precise Spatial Proteomics platform for highly multiplexed immunofluorescence [1] - The EpicIF technology is expected to expand antibody compatibility and double throughput while preserving tissue integrity and preventing cross-reactivity [1][4] Product Details - The CellScape platform, launched in 2022, analyzes protein expression within cellular contexts, providing high-resolution insights into spatial proteomics [2][3] - CellScape allows researchers to map proteins in tissue samples, revealing cell-specific protein patterns and interactions, which is crucial for cancer research, drug discovery, and personalized medicine [3] - EpicIF enhances photobleaching efficacy by combining a proprietary reagent with visible light, allowing for the erasure of fluorescence signals while preserving epitopes and tissue integrity [5] Market Performance - Following the announcement of EpicIF, BRKR shares fell by approximately 4.6% to $57.73, with a year-to-date decline of 21.5%, compared to a 4% decline in the industry and a 26.1% increase in the S&P 500 [2] - Bruker currently has a market capitalization of $8.8 billion [2] Industry Prospects - The global spatial proteomics market was valued at $77.6 billion in 2023 and is projected to grow at a CAGR of 14.8% from 2024 to 2030 [6] - Growth in the market is driven by technological advancements and increasing demand for in-depth protein analysis, particularly through advanced imaging and mass spectrometry techniques [7]